Abstract:Objective To investigate the changes of interleukin-21 (IL 21) and interleukin-21 receptor (IL 21R) expression level in Crohn's disease (CD) patients before and after accepted infliximab (IFX) treatment.Methods From June 2009 to July 2011,twenty-two CD patients met the research criteria were recruited at Tenth People's Hospital of Tongji University.Patients were treated with infliximab at weeks 0,2,6,and 16 healthy individuals were set as healthy control group at same time.Peripheral blood of healthy control group was taken at regular physical examination and blood of CD patients was taken before treatment and 10 weeks after treatment,intestinal mucosa biopsy samples were taken under colon endoscopy examination.The changes of Crohn's disease activity index (CDAI),erythrocyte sedimentation rate (ESR),C-reactive protein (CRP) in CD patients were observed.The change of IL-21R in peripheral blood CD4+ T lymphocytes was detected by flow cytometry.The change of IL-21 expression at mRNA level in intestinal mucosa was determined by realtime quantitative polymerase chain reaction (PCR).The data were analyzed by t test.Results Before treatment,the level of IL21R in peripheral blood CD4+ T lymphocytes of CD patients (12.25％±3.25％) and the expression of IL-21 at mRNA level in inflamed intestinal mucosa (1.38±0.32) were both significantly higher than those of healthy controls (4.25 ％ ± 1.41％,0.44±0.18),the differences were statistically significant (F=15.88,6.75 ; both P＜0.05).At 10th week,the level of IL-21R in peripheral blood CD4+ T lymphocytes of CD patients (8.12％ ± 2.05％) and the expression of IL-21 at mRNA level in intestinal mucosa (0.77 ± 0.24) were both significantly lower than those before treatment,the differences were statistically significant ( t=4.880,8.019; both P＜0.01).Before treatment,ESR,CRP and CDAI of CD patients was (46.8±11.4) mm/1 h,(52.4±11.5) mg/L and 319±74,which was (23.5±9.0) mm/1 h,(11.6±4.6) mg/L and 113±42 after treatment,the differences were statistically significant (t=9.485,16.458,11.100; all P＜0.05).Conclusion The IL-21 expression of active CD patients decreases after IFX treatment,which indicates that IL-21 may involve in IFX induced clinical remission of active CD.

Effect of IL-18 on Peripheral Blood and Lamina Propria Lymphocyte Prolif Eration and Proinflammatory Cytokine Secretion in Patients with Inflammatory Bowel Disease

Effect of IL-12 on peripheral blood and lamina propria lymphocyte activation and proinflammatory cytokine secretion in patients with inflammatory bowel disease

Increased Expression of Interleukin-23 Induces Proinflammatory Cytokine Secretion in Inflammatory Bowel Disease

In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease.

[Expression of Interleukin 18 in Intestinal Mucosa of Patients with Inflammatory Bowel Disease and Its Implications].

Immune Regulation of Interleukin-23 on Peripheral Blood Natural Killer Cell in Patients with Inflammatory Bowel Disease

In Vitro Evaluation of IL-18 Effects in Crohn's Disease

Determination of serum TNF-α and IL-8 in patients with inflammatory bowel disease

The Expression of Interleukin-25 in Patients with Inflammatory Bowel Disease and Its Clinical Significance

Effects of Infliximab Induced Clinical Remission of Active Crohn's Disease on the Level of Interleukin-21 and Interleukin-21 Receptor

Blockage of Tumor Necrosis Factor Prevents Intestinal Mucosal Inflammation Through Down-Regulation of Interleukin-23 Secretion

Significance of interleukin-27 expression in the intestinal mucosa of patients with inflammatory bowel disease

Tumor Necrosis Factor Suppresses Interleukin 10 in Peripheral B Cells Via Upregulating Bcl2-like Protein 12 in Patients with Inflammatory Bowel Disease.

Clinical Evaluation of Lung Function in 74 Patients with Inflammatory Bowel Disease

Expressions and Significance of Interleukin-22,Matrix Metalloproteinase-9 and Macrophage Migration Inhibitory Factor in Peripheral Blood of Patients with Inflammatory Bowel Disease

Expression and Clinical Significance of IL-17BR in Inflammatory Bowel Disease

The Increased Expression of IL-23 in Inflammatory Bowel Disease Promotes Intraepithelial and Lamina Propria Lymphocyte Inflammatory Responses and Cytotoxicity.

Expression of miRNA-21 in colonic mucosa and peripheral blood CD4+ T cells of 49 patients with active inflammatory bowel disease

Dual roles of IL-18 in colitis through regulation of the function and quantity of goblet cells

The Effects of Interleukin-18 on M Cells of Intestinal Mucosa in Murine Acute Pancreatitis

Expression and significance of interleukin-12 family cytokines in peripheral blood of patients with inflammatory bowel disease